Pharmaceutical companies are integrating artificial intelligence and automation into the design-make-test-analyze (DMTA) cycle to accelerate drug discovery, according to industry experts at TTP plc. The approach aims to speed decision-making and iteration cycles, which have historically slowed preclinical research. Connecting workflows between the make and test stages is seen as key to improving productivity and transforming how new drugs reach development.
Quwwaa is your AI news butler — a personalized brief and assistant for the stories you care about.
See more on Quwwaa — create a free account